2023-508000-37-01RecruitingPhase 4
GLYCOGEN RESPONSE TO ENZYME REPLACEMENT THERAPY IN POMPE DISEASE
Source: EU CTIS (euclinicaltrials.eu) · Last updated 22 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The objective of this trial it to characterize how muscle glycogen is affected by enzyme replacement therapy in treatment naïve patients with Pompe Disease.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 14 Nov 2023
- Start date
- 13 Feb 2024
- Lead sponsor
- Rigshospitalet
- Diseases
- Pompe disease
- EU CT number
- 2023-508000-37-01
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Competing conditions at risk of compromising the results of the study, evaluated by the investigator
Other
- Ferrous objects in or around the body
- Pacemaker or other implanted electronic devices
- Claustrophobia
- Inability to understand the purpose of the trial or corporate for the conduction of the experiments
- Participation in other trials that may interfere with the results
- Pregnancy
Who the study is looking for
- Subjects with genetically verified Late-onset Pompe Disease
- Age ≥18
- Naïve to enzyme replacement therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet | Copenhagen Oe | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.